Assoz. Prof. Dr. Thomas Mindt, Privatdoz.
1 - 20 out of 26
Guarrochena, X., Kanellopoulos, P., Stingeder, A., Rečnik, L. M., Feiner, I. V. J., Brandt, M., Kandioller, W., Maina, T., Nock, B. A., & Mindt, T. L. (2024). Amide-to-Triazole Switch in Somatostatin-14-Based Radioligands: Impact on Receptor Affinity and In Vivo Stability. Pharmaceutics, 16(3), [392]. https://doi.org/10.3390/pharmaceutics16030392



Happl, B., Balber, T., Heffeter, P., Denk, C., Welch, J. M., Köster, U., Alliot, C., Bonraisin, A. C., Brandt, M., Haddad, F., Sterba, J. H., Kandioller, W., Mitterhauser, M., Hacker, M., Keppler, B. K., & Mindt, T. L. (2024). Synthesis and preclinical evaluation of BOLD-100 radiolabeled with ruthenium-97 and ruthenium-103. Dalton Transactions. https://doi.org/10.1039/d4dt00118d

Schmitl, S., Raitanen, J., Witoszynskyj, S., Patronas, E. M., Nics, L., Ozenil, M., Weissenböck, V., Mindt, T. L., Hacker, M., Wadsak, W., Brandt, M. R., & Mitterhauser, M. (2023). Quality Assurance Investigations and Impurity Characterization during Upscaling of [177Lu]Lu-PSMAI&T. Molecules, 28(23), [7696]. https://doi.org/10.3390/molecules28237696

Happl, B., Brandt, M., Balber, T., Benčurová, K., Talip, Z., Voegele, A., Heffeter, P., Kandioller, W., Van der Meulen, N. P., Mitterhauser, M., Hacker, M., Keppler, B. K., & Mindt, T. L. (2023). Synthesis and Preclinical Evaluation of Radiolabeled [103Ru]BOLD-100. Pharmaceutics, 15(11), [2626]. https://doi.org/10.3390/pharmaceutics15112626

Wang, Y., Felder, P. S., Mesdom, P., Blacque, O., Mindt, T. L., Cariou, K., & Gasser, G. (2023). Towards Ruthenium(II)-Rhenium(I) Binuclear Complexes as Photosensitizers for Photodynamic Therapy. ChemBioChem, 24(19), [e202300467]. https://doi.org/10.1002/cbic.202300467




Rischka, L., Vraka, C., Pichler, V., Rasul, S., Nics, L., Gryglewski, G., Handschuh, P., Murgas, M., Godbersen, G. M., Silberbauer, L. R., Unterholzner, J., Wotawa, C., Haider, A., Ahmed, H., Schibli, R., Mindt, T., Mitterhauser, M., Wadsak, W., Hahn, A., ... Ametamey, S. M. (2022). First-in-Humans Brain PET Imaging of the GluN2B-Containing N-methyl-D-aspartate Receptor with (R)-C-11-Me-NB1. Journal of Nuclear Medicine, 63(6), 936-941. https://doi.org/10.2967/jnumed.121.262427


Rischka, L., Murgaš, M., Pichler, V., Vraka, C., Rausch, I., Winkler, D., Nics, L., Rasul, S., Silberbauer, L. R., Reed, M. B., Godbersen, G. M., Unterholzner, J., Handschuh, P., Gryglewski, G., Mindt, T., Mitterhauser, M., Hahn, A., Ametamey, S. M., Wadsak, W., ... Hacker, M. (2022). Biodistribution and dosimetry of the GluN2B-specific NMDA receptor PET radioligand (R)-[11C]Me-NB1. EJNMMI Research, 12(1), [53]. https://doi.org/10.1186/s13550-022-00925-8


Rischka, L., Vraka, C., Pichler, V., Rasul, S., Nics, L., Gryglewski, G., Handschuh, P., Murgas, M., Godbersen, G. M., Silberbauer, L. R., Unterholzner, J., Wotawa, C., Haider, A., Ahmed, H., Schibli, R., Mindt, T., Mitterhauser, M., Wadsak, W., Hahn, A., ... Ametamey, S. M. (2021). First-in-human mapping of the GluN2B subunits of the N-methyl-D-aspartate receptor using (R)-[(11)Cc]Me-NB1 and PET. European Journal of Nuclear Medicine and Molecular Imaging, 48(SUPPL 1), 296.

Feiner, I. V. J., Brandt, M., Cowell, J., Demuth, T., Vugts, D., Gasser, G., & Mindt, T. L. (2021). The Race for Hydroxamate-Based Zirconium-89 Chelators. Cancers, 13(17), [4466]. https://doi.org/10.3390/cancers13174466



Vrettos, E., Valverde, I. E., Mascarin, A., Pallier, P. N., Cerofolini, L., Fragai, M., Parigi, G., Hirmiz, B., Bekas, N., Grob, N. M., Shaye, H., Del Borgo, M., Aguilar, M., Magnani, F., Syed, N., Crook, T., Waqif, E., Ghazaly, E., Cherezov, V., ... Stylos, E. K. (2020). Single Peptide Backbone Surrogate Mutations to Regulate Angiotensin GPCR Subtype Selectivity. Chemistry: A European Journal, 26(47), 10690-10694. https://doi.org/10.1002/chem.202000924


1 - 20 out of 26

New Strategies for the Development of Metal-Based Radiopharmaceuticals for the Diagnosis and Therapy of Cancer

Thomas Mindt (Invited speaker)

6 May 2024

Activity: Talks and presentationsTalk or oral contributionScience to Science


Synthesis and Preclinical Evaluation of BOLD-100 Radiolabeled with Ruthenium-97/103

Thomas Mindt (Speaker)

18 Apr 2024

Activity: Talks and presentationsTalk or oral contributionScience to Science


Metabolically Stabilized Triazolo-Peptidomimetics for Improved Tumor-Targeting

Thomas Mindt (Invited speaker)

11 Feb 2024

Activity: Talks and presentationsTalk or oral contributionScience to Science


Radioactive Labeled Molecules for Diagnosis and Therapy of Cancer

Thomas Mindt (Invited speaker)

17 Jan 2024

Activity: Talks and presentationsTalk or oral contributionScience to Science


Evaluation of two albumin-targeting moieties as in situ binders in comparison to maleimide

Anja Federa (Speaker), H. Schueffl (Contributor), Alexander Kastner (Contributor), Julia Kronberger (Contributor), Bernhard Keppler (Contributor), Thomas Mindt (Contributor), P. Heffeter (Contributor) & Christian Kowol (Contributor)

3 Sep 2023

Activity: Talks and presentationsTalk or oral contributionScience to Science


Radiometal-Based Radiopharmaceuticals for Theranostic Approaches in Nuclear Medicine

Thomas L. Mindt (Keynote speaker)

19 Jun 2023

Activity: Talks and presentationsTalk or oral contributionScience to Science


Theranostic Approaches in Radiopharmaceutical Sciences

Thomas L. Mindt (Invited speaker)

14 Mar 2023

Activity: Talks and presentationsTalk or oral contributionScience to Science


Metabolically Stabilized Triazolo-Peptidomimetics for Tumor Targeting

Thomas Mindt (Speaker)

1 Dec 2022

Activity: Talks and presentationsTalk or oral contributionScience to Science


Radiolabeling of [89Zr]Zr-Atezolizumab for its clinical evaluation in patient stratification for PD-L1 immune checkpoint inhibition therapy

Julia Kronberger (Speaker), Thomas Mindt (Contributor), Elisabeth de Vries (Contributor) & Marie Brandt (Contributor)

12 May 2022

Activity: Talks and presentationsTalk or oral contributionScience to Science


Auger electron therapy for cancer treatment

Maximilian Anderla (Speaker) & Thomas Mindt (Contributor)

5 Nov 2021

Activity: Talks and presentationsTalk or oral contributionScience to Science


Peptide-based Radiotracers for PD-L1 PET imaging

Nedra Jouini (Speaker) & Thomas Mindt (Contributor)

5 Nov 2021

Activity: Talks and presentationsTalk or oral contributionScience to Science


Radiolabeling of [89Zr]Zr-Atezolizumab for its clinical evaluation in patient stratification for PD-L1 immune checkpoint inhibition therapy

Julia Kronberger (Speaker), E. de Vries (Contributor), Marie Brandt (Contributor) & Thomas Mindt (Contributor)

5 Nov 2021

Activity: Talks and presentationsTalk or oral contributionScience to Science


First-in-human brain imaging of the GluN2B-containing N-methyl-D-aspartate receptor with (R)-11C-Me-NB1 PET

Lucas Rischka (Speaker), Chrysoula Vraka (Contributor), Verena Pichler (Contributor), Sazan Rasul (Contributor), Lukas Nics (Contributor), Gregor Gryglewski (Contributor), Patricia A. Handschuh (Contributor), Matej Murgaš (Contributor), G. N. Godbersen (Contributor), Leo Silberbauer (Contributor), M. Unterholzner (Contributor), C. Wotawa (Contributor), A. Haider (Contributor), H. Ahmed (Contributor), Roger Schibli (Contributor), Thomas Mindt (Contributor), Markus Mitterhauser (Contributor), Wolfgang Wadsak (Contributor), A. Hahn (Contributor), Rupert Lanzenberger (Contributor), Markus Hacker (Contributor) & Simon M. Ametamey (Contributor)

20 Oct 2021

Activity: Talks and presentationsTalk or oral contributionScience to Science


Radioactive labeled molecules for diagnosis and therapy of diseases

Thomas Mindt (Invited speaker)

11 Oct 2021

Activity: Talks and presentationsTalk or oral contributionScience to Science


Development of Radiometal-Based Theranostics

Thomas Mindt (Invited speaker)

2021

Activity: Talks and presentationsTalk or oral contributionScience to Science


Of Emerging and Established Radiometals

Thomas Mindt (Invited speaker)

2021

Activity: Talks and presentationsTalk or oral contributionScience to Science


Radiometal-Labelled Peptides and Proteins for Diagnosis and Therapy in Nuclear Medicine

Thomas Mindt (Invited speaker)

2021

Activity: Talks and presentationsTalk or oral contributionScience to Science


Jährliche Tagung der Arbeitsgemeinschaft Radiopharmazie und Radiochemie

Thomas Mindt (Speaker)

22 Sep 2019

Activity: Talks and presentationsTalk or oral contributionScience to Science


Matching a Radiometal with a Suitable Chelator - A Case Study for 89Zr-ImmunoPET

Thomas Mindt (Speaker)

26 May 2019

Activity: Talks and presentationsTalk or oral contributionScience to Science


Zirkonium-89 für ImmunoPET in der Nuklearmedizin

Thomas Mindt (Speaker)

3 Feb 2019

Activity: Talks and presentationsTalk or oral contributionScience to Science


Metabolically Stable Triazolo Peptidomimetics for Improved Tumour Targeting

Thomas Mindt (Speaker)

13 Dec 2018

Activity: Talks and presentationsTalk or oral contributionScience to Science


Department of Inorganic Chemistry

Deputy Head
Strahlenschutzbeauftragter

Währinger Straße 42
1090 Wien

T: +43-1-4277-52690

thomas.mindt@univie.ac.at